Toll-like receptors (TLRs) expressed on immune cells trigger inflammatory responses. TLRs are also expressed on ovarian cancer (OvCa) cells, but the consequences of signaling by the TLR4/MyD88 pathway in these cells are unclear. Here, TLR4 and MyD88 expression in OvCa tissues (n ¼ 20) and cell lines (OVCAR3, SKOV3, AD10, A2780 and CP70) was evaluated by reverse transcriptase-PCR, western blots and immunohistochemistry. Cell growth, apoptosis, nuclear factor-jB (NF-jB) translocation, IRAK4 and TRIF expression and cJun phosphorylation were measured following tumor cell exposure to the TLR4 ligands, lipopolysaccharide (LPS) or paclitaxel (PTX). Culture supernatants were tested for cytokine levels. TLR4 was expressed in all tumors, tumor cell lines and normal epithelium. MyD88 was detectable in tumor tissues and in 3/5 OvCa lines but not in normal cells. In MyD88 þ SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-jB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis. Silencing of TLR4 in SCOV3 cells with small interference RNA resulted in phosphorylated-cJun (p-cJun) downregulation and a loss of PTX resistance. In PTXsensitive, MyD88 neg A2780 cells, TLR4 stimulation upregulated TRIF, and TLR4 silencing eliminated this effect. Thus, TLR4/MyD88 signaling supports OvCa progression and chemoresistance, promoting immune escape.
Introduction
Epithelial ovarian cancer (EOC) has the highest mortality rate among patients with gynecologic malignancies (Brewer et al., 2003) . Prognosis remains poor, because most cases of EOC are diagnosed at an advanced stage characterized by high-grade tumors that invariably metastasize. Treatments for primary EOC include surgical cytoreduction followed by adjuvant chemotherapy generally with a paclitaxel (PTX) and cisplatin or carboplatin (Marupudi et al., 2007) . Ovarian cancer (OvCa) is extremely sensitive to this drug combination, and most patients show an initial response to chemotherapy. However, chemoresistance is responsible for the high recurrence rate of OvCa (Berek et al., 1999) . Although the mechanisms responsible for PTX resistance are not well understood, the prevailing hypothesis is that chemoresistant tumor variants acquire growth-promoting characteristics .
Microtubules are the best-characterized cellular target of PTX (Blagosklonny and Fojo, 1999) , which inhibits their depolymerization both in vitro and in vivo. In addition, PTX blocks the cell cycle in mitosis and induces activation of proapoptotic signaling (Taxman et al., 2003) . In murine macrophages, PTX has been reported to mediate endotoxin/lipopolysaccharide (LPS)-like effects, including production of tumor necrosis factor-a, phosphorylation of mitogen-activated protein (MAP) kinases and the release of nitric oxide (Kawasaki et al., 2001) . PTX was thus identified as a Toll-like receptor 4 (TLR4) ligand in murine macrophages (Takeda et al., 2003) . A recent report suggests that development of resistance to PTX in human OvCa may occur through the mechanism involving the TLR4 (Kelly et al., 2006) .
Human TLRs comprise a large family of at least 11 proteins characterized by a member-specific activation and complex downstream signaling (Takeuchi et al., 1999; Chuang and Ulevitch, 2001; Takeda et al., 2003; Zhang et al., 2004) . TLRs are predominantly expressed on various immune cells, serving as cell-surface sensors for pathogens and promoting local inflammation. More recent studies report their expression on a broad variety of tissues, including the female reproductive tract (Girling and Hedger, 2007) , tumor tissues and tumor cell lines, including OvCa (Kelly et al., 2006; Szczepanski et al., 2009) . Although the TLR4 presence on tumor cells has been associated with the extent of inflammatory infiltrates (Backhed and Hornef, 2003; MacRedmond et al., 2005) , the functional significance of TLR expression on tumor cells remains poorly understood. Bacterial LPS, the main TLR4 ligand, shares the receptor with PTX, despite the lack of a structural similarity between these two ligands (Byrd-Leifer et al., 2001; Fitzpatrick and Wheeler, 2003) . TLR4 ligation with either LPS or PTX induces a range of effects in human tumor cells, depending on the cell type, culture conditions and ligand concentrations (Kelly et al., 2006; He et al., 2007) .
TLR4 ligation activates at least two signaling pathways: an MyD88-dependent or a TRIF-dependent pathway (Tanimura et al., 2008) . The former recruits TIRAP and MyD88 for nuclear factor-kB (NF-kB) activation, leading to the upregulation of anti-apoptotic signaling (Kreuz et al., 2004) . The MyD88-independent pathway involves TRAM and instead of MyD88 recruits TRIF and TRAF3, leading to induction of interferon regulatory factor-3 and late NF-kB activation (Takeda and Akira, 2007) . Despite considerable insights into the TLR4 signaling pathway, biologic effects of TLR4 ligation by LPS or PTX in the tumor microenvironment remain controversial.
Here, we explore the mechanisms responsible for the regulation of cellular responses following binding of LPS or PTX to TLR4 in ovarian tumor cells. Investigating TLR4 expression in benign and malignant ovarian tumors in situ and its signaling in human OvCa cell lines, we show that TLR4 has a significant function in growth of ovarian tumor cells and their resistance to PTX.
Results
Expression of TLR4 and MyD88 in ovarian cancer tissues and cell lines Expression of TLR4 was assessed in situ on paraffin sections of normal ovarian tissue adjacent to tumor (n ¼ 10), benign cysts (n ¼ 3), borderline tumors (n ¼ 4) and malignant tumors (n ¼ 20). Table 1 summarizes the pathologic characteristics of tissues. Figure 1 presents the representative immunohistochemistry (IHC) results for TLR4 and MyD88 expression in tissues. TLR4 was found to be expressed in normal ovarian epithelium (Figure 1 (Figure 1  a4) . However, the intensity of staining for TLR4 in malignant tumors was considerably greater than that in normal tissues or benign tumors. Normal ovarian epithelium did not express TLR signaling adapter protein, MyD88 (Figure 1 a5) . A variably strong or weak signal was observed in cancer tissues. The TLR4 and MyD88 expression was next evaluated in human OvCa cell lines: OVCAR3, SKOV3, AD10, A2780 and CP70. Positive immunoreactivity for TLR4 was observed in all of the evaluated cell lines by staining of cell smears (Figure 1 b2 ) and by western blots or reverse transcriptase (RT)-PCR ( Figure 1c ). No staining was observed when IgG1 was used as a negative control (Figure 1 b1) . SKOV3, OVCAR3 and AD10 cells were MyD88 þ , whereas A2780 and CP70 were MyD88 neg as shown by immunofluorescence (Figures 1 b3 and b4) . Western blots further confirmed the expression of MyD88 in OVCAR3, SKOV3 and AD10 cells, but not in A2780 and CP70 cells (Figure 1c) .
Two OvCa cell lines A2780 and SKOV3 were chosen for further studies. The A2780 cell line was derived from a primary untreated and PTX-sensitive cancer (Behrens et al., 1987) . In contrast, the SKOV3 cell line was obtained from the ascites of a patient with advanced, metastatic OvCa. SKOV3 is resistant to most cytotoxic drugs (Cuello et al., 2001) .
LPS induces proliferation in SKOV3 but not A2780 cells Tumor cells (1 Â 10 4 cells per well) were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE), incubated with increasing concentrations of LPS (0-15 mg/ml) for 5 days and analysed for proliferation. As shown in Figure 2a (left), LPS used at the optimal concentration of 10 mg/ml induced proliferation of SKOV3 cells (proliferation index, PI ¼ 12.9) relative to untreated cells (PI ¼ 8.3) but had no effect on proliferation 
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TLR4 signaling in ovarian cancer M Szajnik et al of A2780 cells. In contrast to LPS, PTX inhibited proliferation in both cell lines (Figure 2b , left). In the presence of PTX, the cell viability decreased as the dose of PTX increased (1-20 mm). A2780 cells were found to be significantly more sensitive to PTX than SKOV3 (Figure 2b , right).
ANX-V binding to tumor cells incubated with LPS or PTX
Annexin V (ANX-V) binding to tumor cells before and after exposure to LPS and PTX was measured to evaluate apoptosis. In control cultures, spontaneous apoptosis ranged from 2 to 8%, and it remained unchanged after stimulation with LPS alone (Table 2) . PTX induced significant apoptosis levels in A2780 cells after 24 and 48 h incubation. In contrast, SKOV3 cells were relatively resistant to PTX-induced apoptosis (Table 2) .
NF-kB signaling
Translocation of the p65 subunit of NF-kB to cell nuclei, and NF-kB p65 binding activity were evaluated within 2 h of tumor cells stimulation with LPS or PTX.
The baseline translocation of p65 subunit ( Figure 3a ) occurred in 23 ± 5% (mean ± s.d.) SKOV3 cells and in 36±9% A2780 cells. After LPS or PTX addition, the percentage of SKOV3 cells with the p65 subunit translocation significantly increased ( Figure 3b ). Also, the mean fluorescence intensity (MFI) of nuclear NF-kB was significantly increased in SKOV3 cells after exposure to LPS or PTX, whereas no changes were observed in A2780 cells ( Figure 3c ). Binding activity of p65 to cellular DNA in SKOV3 cells further indicated that LPS or PTX induced activation of the NF-kB pathway ( Figure 3d ). In contrast, no NF-kB activation was observed in A2780 cells on LPS or PTX addition (Figures 3b-d ).
TLR4 signaling pathways in ovarian carcinoma cell lines
The observed differential responses of the two cell lines to LPS or PTX signaling could reflect the presence or absence of MyD88 in tumor cells (Kelly et al., 2006) . As shown in Figure 4 , SKOV3 cells constitutively expressed MyD88, whereas A2780 cells did not. In addition, signaling downstream of TLR4 in response to LPS and PLX induce cytokine production in SKOV3 but not in A2780 cells Supernatants of both cell lines exposed to LPS or PTX for 48 h were analysed for levels of inflammatory cytokines and growth factors. SKOV3 cells constitutively secreted a wide range of cytokines and chemokines, including interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF) and monocyte chemotactic protein-1 (MCP-1). In contrast, A2780 did not produce or produced low levels of these cytokines. 
Effects of TLR4-specific siRNA
To further probe the function of TLR4 in cancer cells, we pretreated SKOV3 and A2780 cells with small interference RNA (siRNA) specific for TLR4 or scrambled siRNA. Tumor cells silenced by siRNA lacked the expression of TLR4 at the mRNA and protein levels for at least 8 days when tested by RT-PCR and western blots on day 4, 8 and 12 (Figure 6a ). The effects of gene silencing on ANX-V binding evaluated on day 4, consistently showed that SKOV3 cells became highly sensitive to PTX after TLR4 silencing. In contrast, PTX-sensitive A2780 cells showed no change in the frequency of ANX-V þ cells after TLR4 silencing (Figure 6b ). Cytokine production in response to LPS and PTX stimulation was significantly inhibited in SKOV3 cells in the presence of TLR4-specific siRNA (compare Figure 6c to Figure 4) . No changes in cytokine production were observed in A2780 cells.
TLR4 silencing was accompanied by the significant (Po0.05) downregulation of p-cJun expression in SKOV3 cells at 30 and 60 min after treatment with LPS or PTX (Figure 6d ). In contrast, no such change was observed in A2780 cells. There was no significant change in expression of IRAK4 in either cell line; however, TRIF upregulation evident in LPS-and PTX-treated A2780 cells was no longer evident following TLR4 silencing. This confirms that the TRIF pathway is dependent on TLR4 signaling in A2780 cells. The data suggest that PTX mediates its biologic effects through TLR4 activation in SKOV3 cells and in A2780 cells.
Discussion
The presence of TLRs on cancer cells has been reported only recently (Kelly et al., 2006; Szczepanski et al., 2007) , and the function of these receptors in cancer progression and resistance to therapy remains questionable 5 cells per well after 48 h of treatment and tested for levels of various cytokines as described in Materials and methods section. Three independent experiments were performed. Asterisks indicate differences (Po0.05) between experimental and control cultures. Fukata and Abreu, 2008) . In respect to TLR4, evidence supporting its involvement in cancer growth and sensitivity to apoptosis mediated by drugs or immune cells is available for ovarian carcinoma (Kelly et al., 2006) , head and neck cancer (Szczepanski et al., 2009) and lung cancer (He et al., 2007) . In ovarian carcinoma, TLR4 signaling in ovarian cancer M Szajnik et al Kelly et al. (2006) first reported that the TLR4 expression is related to PTX resistance. Our study using two TLR4 þ cell lines, A2780 and SKOV3, derived from primary and metastatic tumors, respectively, shows that TLR4 signaling promotes tumor growth and drug resistance in metastatic ovarian carcinoma but not in primary tumors.
In SKOV3 cells, TLR4 was functional, as LPS induced proliferation, activation of NF-kB, p65 binding to DNA and production of pro-inflammatory cytokines (IL-6, IL-8) and VEGF as well as chemokine MCP-1. In A2780 cells, LPS induced an increase in TRIF expression after 30 min, and more clearly after 60 min, suggesting that TLR4 signaling in these cells is also dependent on LPS. The two cell lines differed in their response to PTX, which has been reported to signal by TLR4 (Byrd-Leifer et al., 2001; Kelly et al., 2006) . PTX induced TRIF upregulation and death in A2780 cells, whereas SKOV3 cells were resistant to the drug. Thus, in A2780, but not in SKOV3, TLR4 was responsive to PTX signaling. The mechanism(s) responsible for PTX resistance in OvCa is not completely understood (Duan et al., 1999) and may involve a loss of p53 function (Petty et al., 1998) . SKOV3 cells that lack the p53 gene (Cuello et al., 2001 ) are resistant to DNA-damaging agents and unable to initiate apoptosis (Hollstein et al., 1997; Cimoli et al., 2004) , whereas A2780 cells that express wt p53 are chemosensitive. A2780 cells become resistant to cytotoxic drugs after transfection with a mutated p53 (Gallardo et al., 1996; Cimoli et al., 2004) . However, the p53 status alone is not the only determinant of sensitivity/resistance to cytotoxic drugs. Because the understanding of cellular and molecular mechanisms by which PTX exerts its effect on OvCa is of critical clinical importance, we tested the hypothesis that ovarian carcinoma sensitivity to PTX depends on the integrity of signaling by TLR4.
It has been reported that MyD88 is an essential downstream component of the TLR4 signaling cascade mediating PTX resistance (Jordan and Wilson, 2004; Kelly et al., 2006) . In our study, SKOV3 cells, which are resistant to PTX, expressed MyD88, upregulated IRAK4 expression and mediated cJun phosphorylation on exposure to PTX. Moreover, in SKOV3 cells, PTX signaling by TLR4 induced the NF-kB pathway activation and nuclear translocation associated with the increased transcription of a number of different genes and production of proinflammatory cytokines. These effects of NF-kB activation in tumor cells have been previously linked to upregulation of antiapoptotic protein expression and an increase in cell proliferation (Landen et al., 2008) . It is thus possible to speculate that in vivo utilization of TLR4 by cancer cells, leading to NF-kB activation, and proinflammatory cytokine production allow them to progress and metastasize, and acquire resistance to chemotherapy. In contrast, in A2780 cells, which do not express MyD88, the lack of this adaptor protein caused the engagement of the TRIF pathway in response to TLR4 stimulation. However, A2780 cells remain sensitive to PTX, suggesting that the induction of apoptosis by PTX is independent of TRIF signaling and is probably mediated by the interaction of PTX with an alternative receptor (Wang et al., 2006) , which is fully functional in the absence of TLR4 signaling following its siRNA silencing.
If TLR4 signaling provides a survival benefit to tumor cells and alters their sensitivity to PTX, then its silencing by siRNA should help in identifying the molecular mechanisms responsible for LPS-and PTX-mediated effects. Indeed, silencing of TLR4 expression in SKOV3 resulted in sensitization of SKOV3 cells to PTX-induced apoptosis, and this sensitization was accompanied by the inhibition of cytokine production in response to PTX and LPS. Among the downstream MAP kinases activated by LPS or PTX in SKOV3 cells, cJun appears to be important in OvCa resistance to chemotherapy. The loss of cJun phosphorylation on PTX binding to TLR4 was associated with a loss of resistance to PTX in SKOV3 cells. Thus, up-or downregulation of cJun phosphorylation downstream of TLR4 appears to be a major molecular mediator of PTX-induced as well as LPS-induced signaling. The effects of TLR4 silencing on SKOV3 but not on A2780 cells suggest that this signaling pathway is utilized by metastatic tumor cells to promote their own survival. The development of PTX resistance appears to be associated with the expression of functional TLR4 in SKOV3 cells. We show that cJun phosphorylation is one of the signals downstream of TLR4 that participates in developing PTX resistance in ovarian carcinoma.
Interestingly, activation of cJun has been reported to be a major stimulator of the IL-6 gene regulation (Wang et al., 2006) , linking molecular with cellular effects of PTX signaling by TLR4. In many human cancers, IL-6 production and its increased circulating levels have emerged as a biomarker of poor prognosis (Penson et al., 2000) . In OvCa, increased levels of IL-6 in patients' sera were linked to tumor progression (Hefler et al., 2003) , resistance to apoptosis and chemoresistance (Duan et al., 1999) . We have observed significantly increased production of IL-6 by SKOV3 cells after PTX and LPS binding to TLR4. In addition to IL-6, PTX induced the release of other cytokines in SKOV3 cells, which might be considered as tumor-promoting factors. IL-8 has been reported to be overexpressed in OvCa and its level associated with decreased patient survival and poor clinical outcome (Kassim et al., 2004; Lokshin et al., 2006) . VEGF, in addition to inducing angiogenesis, is also an immunosuppressive cytokine that contributes to promoting ascites formation through stimulation of vascular permeability and promoting angiogenesis (Senger et al., 1983; McClure et al., 1994) . The production of these cytokines after PTX binding to TLR4 in SKOV3 suggests that this mechanism operative in vivo could significantly contribute to tumor cell survival and their chemoresistance.
Our data suggest that TLR4 signaling represents a potential therapeutic target for OvCa. A better understanding of the molecular mechanisms contributing to drug resistance is necessary for the development of novel strategies that are most likely to eliminate drug TLR4 signaling in ovarian cancer M Szajnik et al resistance and thus improve prognosis and survival of patients with OvCa.
Materials and methods

Reagents
Cell culture reagents, including RPMI 1640 medium, phosphate-buffered saline (PBS), heat-inactivated fetal calf serum (FCS), streptomycin, penicillin, recombinant trypsin-like enzyme (TripleSelect) and the Trypan-blue dye were purchased from Invitrogen (Carlsbad, CA, USA). LPS was purchased from Sigma-Aldrich (St Louis, MO, USA) and PLX from Bedford Laboratories (Bedford, OH, USA).
Tumor cell lines
Human OvCa cell lines OVCAR3, SKOV3, AD10, A2780 and CP70 were provided by Dr S Khlief, NIH, Bethesda, MD and were cultured in RPMI 1640 medium supplemented with 10% (v/v) FCS, 2 mm L-glutamine, 100 U/ml penicillin and 100 mg/ ml streptomycin at 37 1C in an atmosphere of 5% CO 2 in air. Tumor cell lines were tested for Mycoplasma and confirmed to be negative.
Samples
Samples of benign tumors (n ¼ 3), borderline tumors (n ¼ 4) and OvCa (n ¼ 20) were collected with the approval of the ethics committee of the University of Medical Sciences in Poznan, Poland.
RNA isolation and RT-PCR
Total RNA was isolated from cancer cells as previously described (Szczepanski et al., 2009) using Trizol reagent (Invitrogen) and reverse transcribed to cDNA. cDNA transcripts were then amplified using the following primers specific for TLR4: F, 5 0 -CTGCAATGGATCAAGGACCA-3 0 ; R, 5 0 -TCCCACTCCAGGTAAGTGTT-3 0 (Lauzon et al., 2006) . PCR was carried out using the following conditions: denaturation at 95 1C for 45 s, annealing at 60 1C for 45 s, and extension at 72 1C for 60 s.
Immunostaining
Tumor cells deposited on glass slides were fixed in 2% (w/v) paraformaldehyde in PBS for 15 min, permeablized with 0.1% (w/v) Triton X in PBS, washed and blocked with 2% (w/v) bovine serum albumin (Sigma-Aldrich) in PBS for 4 min. Polyclonal goat anti-human TLR4 antibodies (Abs) (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:100) or polyclonal rabbit anti-human MyD88 Abs (Cell Signaling Technology, Danvers, MA, USA; 1:100) served as primary reagents. Cy3-labeled (1:500) or fluorescein isothiocyanate (FITC)-labeled (1:200) donkey anti-rabbit IgG served as secondary Abs (Jackson ImmunoResearch, West Grove, PA, USA). To eliminate nonspecific Ab binding, we incubated slides in 10% normal donkey serum for 1 h before incubation with the primary Abs for 1 h at room temperature (RT) in a moist chamber. Slides were then washed in PBS and incubated with the secondary Abs for 45 min at RT in the dark. In control samples, primary Abs were omitted or goat serum was used instead of primary Abs. Sections were mounted in a medium with 46-diamidino-2-phenyl indole (DAPI; Vector Laboratories, Burlingame, CA, USA) to visualize cell nuclei. Slides were evaluated with the Olympus Provis (Olympus, Center Valley, PA, USA) fluorescence microscope under Â 400 magnification, and Adobe Photoshop 6.0 was used for digital image analysis.
Immunohistochemistry
Paraffin sections of tumor tissues were deparaffinized, microwaved whereas immersed in 0.01 M citrate buffer (pH 6.0) for 20 min, washed with PBS and incubated overnight at 4 1C with polyclonal rabbit anti-human TLR4 Abs (Abcam, Cambridge, MA, USA; 1:50) or with polyclonal goat anti-human MyD88 Abs (Abcam; 3 mg/ml). After washing, tissues were incubated with horseradish peroxidase (HRP)-labeled anti-rabbit or anitgoat Ab, respectively, for 1 h, followed by 3,3 0 diaminobenzidine (Dako, Carpinteria, CA, USA). Tissue section were counterstained with hematoxylin (Sigma-Aldrich) and mounted in glycerol jelly. In control sections, primary Abs were omitted. The IHC results for TLR4 and MyD88 expressed in tissues were scored by two independent investigators (MS and EE) based on the level of staining intensity as none (À), weak ( þ ), moderate ( þþ ) or strong ( þþ þ ).
Incubation of tumor cells with TLR4 ligands
In all experiments testing effects of LPS or PTX on tumor cells, LPS was used at the concentration of 10 mg/ml and PTX at 1 or 20 mm.
Annexin V binding A flow-based ANX-V assay was used to measure ovarian tumor cell apoptosis as previously described (Martin et al., 1995) . Briefly, cells were treated with PTX, LPS or medium for 24 h, washed in PBS, resuspended in ANX-V-binding buffer and stained with 1 mg/ml FITC-conjugated ANX-V (SigmaAldrich) for 15 min on ice in the dark. Tumor cell apoptosis was evaluated by flow cytometry, gating on forward angle scatter and side angle scatter to identify ANX-V þ cells as previously described (Szczepanski et al., 2009) .
CFSE-based proliferation assays
Tumor cells were labeled with 1.5 mm CFSE (Invitrogen) and stimulated with LPS or PTX. Cells were incubated for 5 days and CFSE dilution was measured by flow cytometry. The data were analysed using the ModFit LT for Win32 software (Verity Software Housen, Inc., Topsham, ME, USA). The program calculates the PI based on the dilution levels of CFSE detected in dividing cells (Strauss et al., 2007) .
Cytokine and chemokine production Cytokines and chemokine production by tumor cells was determined using the immunobead-based multiplex assays (Luminex). Supernatants of tumor cells seeded in 12-well plates at 5 Â 10 5 cells per well in 1 ml of medium±LPS or ± PTX were collected after 48 h incubation. The levels of IL-1b, IL-2, IL-4, IL-6, IL-8, GM-CSF, VEGF, fibroblast growth factor (FGF), IP-10, MIG-1, RANTES, MCP-1 and MIP-1 were measured using panels of capture Ab-coated beads and the labeled detection Abs, which were pretested and qualified by the manufacturer to ensure the absence of crossreactivity. The assay sensitivity varied from 5 to 15 pg/ml.
Western blots analysis
OvCa cells were stimulated with LPS or PTX for different periods of time and lysed in the presence of a protease inhibitor cocktail (Pierce Chemical, Rockford, IL, USA). Proteins separated by SDS-polyacrylamide gel electrophoresis were electrotransferred to polyvinylidene difluoride membranes. The following Abs: anti-MyD88, anti-cJun, anti-IRAK4, TLR4 signaling in ovarian cancer M Szajnik et al anti-TRIF (all from Cell Signaling Technology) and anti-TLR4 (Abcam) were used for detection, and HRP-conjugated secondary Abs (Pierce Chemical; 1:150 000 dilution) for development of reactions in a chemiluminescent detection system (Pierce Chemical). b-Actin Abs were used as controls for equal protein loading.
NF-kB assays
Cancer cells were plated overnight in 96-well plates at 15 Â 10 3 cells per well. Following 2 h incubation with LPS or PTX, cells were fixed and stained for translocation of the NF-kB p65 subunit using rabbit anti-p65 Abs (Santa Cruz Biotechnology) and FITC-labeled donkey anti-rabbit IgG. Cells were counted and stained with Hoechst 33342 dye and the cells analysed in a Cellomics ArrayScan HCS reader as previously described (Siervo-Sassi et al., 2003) . To measure the p65 subunits binding activity, we prepared nuclear and cytoplasmic extracts using a TransFactor extraction kit (Clontech, Mountain View, CA, USA). DNA binding by p65 was detected by enzymelinked immunosorbent assay using a TransFactor prolfiling kit (Clontech) (Bayry et al., 2004) . To visualize translocation of the p65 subunit of NF-kB to cell nuclei±LPS or±PTX, we examined tumor cells (1 Â 10 4 ) stained using rabbit anti-p65 Abs by confocal microscopy as described (Szczepanski et al., 2009) . Cells with evidence of NF-kB p65 translocation were counted by examining at least 200 tumor cells in an inverted Olympus FluoView 1000 laser scanning confocal microscope under an oil immersion objective.
Silencing of TLR4 using siRNA TLR4 expression was temporarily silenced in tumor cells using siRNA as previously described (Huang et al., 2005; Eskan et al., 2008) . To determine the optimal working concentration of TLR4 siRNA, we seeded 2 Â 10 5 cells in wells of six-well plates, cultured in medium, harvested at confluence and resuspended in the transfection medium containing increasing siTLR4 concentrations (4, 8, 10 or 12 ml). For TLR4 silencing, cells were incubated with siRNA (8-10 ml) for 6 h in an atmosphere of CO 2 in air at 37 1C and then allowed to recover in medium for 24 h. Scrambled siRNA, with no homology to known human sequences, was used as control. The transfected cells were treated with LPS or PTX as described above. In parallel cultures, the frequency of transfected cells was evaluated by fluorescence microscope, using nontargeting siRNA-FITC. Cultures with transfection efficiency >80% were used for further studies. Viability of transfected tumor cells was tested by Trypan-blue exclusion, and the expression of targeted genes in tumor cells was tested on day 4, 8 and 12 by RT-PCR and western blots.
Statistical analysis
Data were summarized by descriptive statistics (the mean and standard deviation for continuous variables; the frequency and percentage for categorical variables). All statistical analyses were performed using the Student's t-test, and P-values o0.05 were considered significant.
